Rheumatoid Arthritis Moderate | Rheumatoid Arthritis Severe | golimumab
Item
participants with moderate to severe ra for whom the physician had decided to treat with golimumab according to the local product label, with the first dose being administered between 12 and 26 weeks prior to study enrollment
boolean
C0003873 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2353893 (UMLS CUI [3])
Fair therapeutic response | Golimumab Dose Regular
Item
participants who have achieved an adequate therapeutic response to regular doses of golimumab, within 12 to 26 weeks of treatment
boolean
C0184784 (UMLS CUI [1])
C2353893 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205272 (UMLS CUI [2,3])
Evaluation Exposure to Tuberculosis | Evaluation Exposure to Risk factors | Management Tuberculosis | Management Latent Tuberculosis
Item
participants should be evaluated for tuberculosis (tb) exposure/risk factors or managed for active and latent tb (per local requirements and according to the local product label)
boolean
C1261322 (UMLS CUI [1,1])
C0332157 (UMLS CUI [1,2])
C0041296 (UMLS CUI [1,3])
C1261322 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
C0035648 (UMLS CUI [2,3])
C0376636 (UMLS CUI [3,1])
C0041296 (UMLS CUI [3,2])
C0376636 (UMLS CUI [4,1])
C1609538 (UMLS CUI [4,2])
Evaluation Hepatitis B Virus | Evaluation Hepatitis B Virus Latent | Evaluation Hepatitis C virus | Evaluation Hepatitis C virus Latent
Item
participants who have been evaluated for active/latent hepatitis b virus (hbv) and hepatitis c virus (hcv)
boolean
C1261322 (UMLS CUI [1,1])
C0019169 (UMLS CUI [1,2])
C1261322 (UMLS CUI [2,1])
C0019169 (UMLS CUI [2,2])
C0205275 (UMLS CUI [2,3])
C1261322 (UMLS CUI [3,1])
C0220847 (UMLS CUI [3,2])
C1261322 (UMLS CUI [4,1])
C0220847 (UMLS CUI [4,2])
C0205275 (UMLS CUI [4,3])
Availability of Medical Record Complete
Item
participants for whom, since golimumab initiation, a complete medical record is available
boolean
C0470187 (UMLS CUI [1,1])
C0025102 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Golimumab Treatment completed In the past
Item
participants who have received and terminated golimumab treatment in the past
boolean
C2353893 (UMLS CUI [1,1])
C0580352 (UMLS CUI [1,2])
C1444637 (UMLS CUI [1,3])
Golimumab Duration of treatment | Status pre- Enrollment
Item
participants that have been treated with golimumab for more than 26 weeks prior to enrolment in the study
boolean
C2353893 (UMLS CUI [1,1])
C0444921 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C1516879 (UMLS CUI [2,2])
Investigational New Drugs
Item
participants with use of any other investigational agent less than or equal to 30 days before starting treatment with golimumab
boolean
C0013230 (UMLS CUI [1])
Latent Tuberculosis Suspected | Prophylactic treatment Duration Absent
Item
participants with suspected latent tb, having not received prophylactic treatment of at least 4 weeks
boolean
C1609538 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0199176 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Tuberculosis Suspected | Tuberculosis
Item
participants with suspected or active tb
boolean
C0041296 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0041296 (UMLS CUI [2])
Hepatitis B Virus | Hepatitis C virus | Hepatitis B Virus Latent | Hepatitis C virus Latent
Item
participants with active/latent hbv or hcv
boolean
C0019169 (UMLS CUI [1])
C0220847 (UMLS CUI [2])
C0019169 (UMLS CUI [3,1])
C0205275 (UMLS CUI [3,2])
C0220847 (UMLS CUI [4,1])
C0205275 (UMLS CUI [4,2])